Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure

• Status: Not yet recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is a prospective, multi-center, randomized, open-ended, double-arm clinical study. All eligible patients were randomly assigned to DEB-BACE combined with PD-1 inhibitor (Sindilizumab) treatment group (test group) and DEB-BACE treatment group (control group), to explore the efficacy and safety of combination therapy for stage II/III NSCLC with standard treatment failure or intolerable patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Central Hospital of Lishui City
• Collaborators: Jiangxi Chest Hospital; Jiangxi Provincial Cancer Hospital; The First Affiliated Hospital of Zhengzhou University; Zhejiang University
• Treatments: Immune Checkpoint Inhibitors

Criteria

Inclusion Criteria:

• Age more than 18 years old, no gender limit.

• According to the Diagnosis and Treatment of Primary Lung Cancer (2018 edition), non-small cell lung cancer (NSCLC) was diagnosed by histopathology.

• Tumor Node Metastasis (TNM) staging is II-III.

• According to the National Comprehensive Cancer Network (NCCN) guidelines, patients who had failed, refused, or were not suitable for standard treatment (surgery, chemoradiotherapy, targeted) after consultation.

• Eastern Cooperative Oncology Group (ECOG), Performance Status (PS) Score ≤ 2.

• Estimated survival time is more than 3 months.

• The patient has signed informed consent.

Exclusion Criteria:

• The patient has previously received interventional therapy [iodine seed implantation, ablation, bronchial arterial chemoembolization (BACE) therapy], or received immunotherapy during the first-line standard treatment.

• The patient is accompanied by other malignant tumors and had not been cured.

• White blood cell < 3×10*9/L, absolute value of neutrophils < 1.5×10*9/L, neutrophil/lymphocyte ratio ≥ 3, platelet count < 50×10*9/L, hemoglobin concentration < 90 g/L.

• Liver and kidney dysfunction (creatinine > 176.8 μmol/L; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2 times the upper limit of normal).

• Uncorrectable coagulopathy or active hemoptysis.

• Patient with active infections requires antibiotic treatment.

• Patient has uncontrollable hypertension, diabetes, and cardiovascular disease with obvious symptoms.

• Allergy to contrast agents.

• Women with pregnancy or lactation.